Fig. 8

LATS2 overexpression leads to the reduction of TAZ, which induces tumor development and correlates with prognosis in ESCC. a-c QRT-PCR and western blot analysis showed that LATS2 could negatively regulate TAZ expression of ESCC cells. b Western blot for LATS2 antibody. d Immunohistochemical staining of TAZ protein in primary ESCC tissue samples (Left: ×200; Right: ×400). e Kaplan-Meier survival plots analysis of the association of TAZ with the OS and PFS of ESCC patients. f Rescue assay confirmed that overexpression of TAZ partially reverse the effects of LATS2 inhibition in ESCC cells via qRT-PCR Values are mean ± SD. g Analysis of correlation between miR-31 and LATS2/TAZ, LATS2 and TAZ expression levels in 164 ESCC tissues specimens. *: P < 0.05; **: P < 0.01